<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Fludrocortisone</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00687</strong>&#160; (APRD00756, DB02478)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A synthetic mineralocorticoid with anti-inflammatory activity. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00687/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00687/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00687.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00687.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00687.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00687.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00687.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00687">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Fludrocortison</td><td>German</td><td>INN</td></tr><tr><td>Fludrocortisona</td><td>Spanish</td><td>INN</td></tr><tr><td>Fludrocortisone</td><td>French</td><td>INN</td></tr><tr><td>Fludrocortisonum</td><td>Latin</td><td>INN</td></tr><tr><td>Fluohydrocortisone</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Fludrocortisone Acetate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000659/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000659/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: SYWHXTATXSMDSB-GSLJADNHSA-N</li>
              <li>Monoisotopic Mass: 422.210466929</li>
              <li>Average Mass: 422.487</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000659">DBSALT000659</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Adixone</td><td>Genopharm</td></tr><tr><td>Astonin</td><td>Merck</td></tr><tr><td>Cortineff</td><td>Polfa Pabianice</td></tr><tr><td>Florinef Acetaat</td><td>Bristol-Myers Squibb</td></tr><tr><td>Florinefe</td><td>Bristol-Myers Squibb</td></tr><tr><td>Fludrocortison</td><td>Bristol-Myers Squibb</td></tr><tr><td>Lonikan</td><td>Merck</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Neoproct</td><td>Fludrocortisone and Lidocaine</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-inflammatory-agents">Anti-Inflammatory Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>127-31-1</td></tr><tr><th>Weight</th><td>Average: 380.4504<br>Monoisotopic: 380.199902243</td></tr><tr><th>Chemical Formula</th><td>C<sub>21</sub>H<sub>29</sub>FO<sub>5</sub></td></tr><tr><th>InChI Key</th><td>AAXVEMMRQDVLJB-BULBTXNYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C21H29FO5/c1-18-7-5-13(24)9-12(18)3-4-15-14-6-8-20(27,17(26)11-23)19(14,2)10-16(25)21(15,18)22/h9,14-16,23,25,27H,3-8,10-11H2,1-2H3/t14-,15-,16-,18-,19-,20-,21-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(1R,2S,10S,11S,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Lipids</td></tr><tr><th>Class</th><td>Steroids and Steroid Derivatives</td></tr><tr><th>Subclass</th><td>Gluco/mineralocorticoids, Progestogins and Derivatives</td></tr><tr><th>Direct parent</th><td>Gluco/mineralocorticoids, Progestogins and Derivatives</td></tr><tr><th>Alternative parents</th><td>Hydroxysteroids; Halogenated Steroids; Ketosteroids; Cyclohexanols; Tertiary Alcohols; Ketones; Cyclic Alcohols and Derivatives; Fluorohydrins; Enolates; Polyamines; Primary Alcohols; Organofluorides; Alkyl Fluorides; Aldehydes</td></tr><tr><th>Substituents</th><td>20-keto-steroid; 11-hydroxy-steroid; 9-halo-steroid; 17-hydroxy-steroid; 3-keto-steroid; cyclohexanol; cyclic alcohol; tertiary alcohol; secondary alcohol; ketone; fluorohydrin; halohydrin; enolate; primary alcohol; polyamine; organofluoride; organohalogen; alcohol; carbonyl group; alkyl halide; alkyl fluoride; aldehyde</td></tr><tr><th>Classification description</th><td>This compound belongs to the gluco/mineralocorticoids, progestogins and derivatives. These are steroids whose structure is based on an hydroxylated prostane moiety.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome.</td></tr><tr><th>Pharmacodynamics</th><td>Fludrocortisone is a synthetic adrenocortical steroid possessing very potent mineralocorticoid properties and high glucocorticoid activity. It is indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison&#8217;s disease and for the treatment of salt-losing adrenogenital syndrome. The physiologic action of fludrocortisone acetate is similar to that of hydrocortisone. However, the effects of fludrocortisone acetate, particularly on electrolyte balance, but also on carbohydrate metabolism, are considerably heightened and prolonged. Mineralocorticoids act on the distal tubules of the kidney to enhance the reabsorption of sodium ions from the tubular fluid into the plasma; they increase the urinary excretion of both potassium and hydrogen ions.</td></tr><tr><th>Mechanism of action</th><td>Fludrocortisone binds the mineralocorticoid receptor (aldosterone receptor). This binding (or activation of the mineralocorticoid receptor by fludrocortisone) in turn causes an increase in ion and water transport and thus raises extracellular fluid volume and blood pressure and lowers potassium levels.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>High</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic, some renal.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>3.5 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Effects of overexposure include irritation, cardiac edema, increased blood volume, hypertension, cardiac arrhythmias, enlargement of the heart, headaches, and weakness of the extremities.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9927</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9731</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8415</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7911</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8385</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9351</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7774</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8799</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.909</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7138</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9306</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9023</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9201</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9285</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8772</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.903</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8895
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9479
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9964
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.1686 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9591
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.5213
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>King pharmaceuticals inc</li>
<li>Barr laboratories inc</li>
<li>Impax laboratories inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li>Avkare Incorporated</li>
<li>Barr Pharmaceuticals</li>
<li><a href="http://www.bms.com">Bristol-Myers Squibb Co.</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li>E.R. Squibb and Sons LLC</li>
<li><a href="http://www.globalphar.com">Global Pharmaceuticals</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.impaxlabs.com">Impax Laboratories Inc.</a></li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li>Vangard Labs Inc.</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>The corticosteroid, fludrocortisone, alters the anticoagulant effect, acenocoumarol.</td></tr><tr><td><a href="/drugs/DB00945">Acetylsalicylic acid</a></td><td>The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, acetylsalicylic acid.</td></tr><tr><td><a href="/drugs/DB01122">Ambenonium</a></td><td>The corticosteroid, fludrocortisone, may decrease the effect of the anticholinesterase, ambenonium.</td></tr><tr><td><a href="/drugs/DB01351">Amobarbital</a></td><td>The barbiturate, amobarbital, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>The corticosteroid, fludrocortisone, alters the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB01352">Aprobarbital</a></td><td>The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB01294">Bismuth Subsalicylate</a></td><td>The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, bismuth subsalicylate.</td></tr><tr><td><a href="/drugs/DB00237">Butabarbital</a></td><td>The barbiturate, butabarbital, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB00241">Butalbital</a></td><td>The barbiturate, butalbital, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB01353">Butethal</a></td><td>The barbiturate, butethal, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>The corticosteroid, fludrocortisone, alters the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB01341">Dihydroquinidine barbiturate</a></td><td>The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB01010">Edrophonium</a></td><td>The corticosteroid, fludrocortisone, may decrease the effect of the anticholinesterase, edrophonium.</td></tr><tr><td><a href="/drugs/DB00754">Ethotoin</a></td><td>The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB01354">Heptabarbital</a></td><td>The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB01355">Hexobarbital</a></td><td>The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB01397">Magnesium salicylate</a></td><td>The corticosteroid, fludrocortisone, may decrease the effect of magnesium salicylate. </td></tr><tr><td><a href="/drugs/DB00532">Mephenytoin</a></td><td>The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB00474">Methohexital</a></td><td>The barbiturate, methohexital, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB00849">Methylphenobarbital</a></td><td>The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB00211">Midodrine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01400">Neostigmine</a></td><td>The corticosteroid, fludrocortisone, may decrease the effect of the anticholinesterase, neostigmine.</td></tr><tr><td><a href="/drugs/DB00312">Pentobarbital</a></td><td>The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB01174">Phenobarbital</a></td><td>The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB00794">Primidone</a></td><td>The barbiturate, primidone, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB00545">Pyridostigmine</a></td><td>The corticosteroid, fludrocortisone, may decrease the effect of the anticholinesterase, pyridostigmine.</td></tr><tr><td><a href="/drugs/DB01346">Quinidine barbiturate</a></td><td>The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB01398">Salicylate-sodium</a></td><td>The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, salicylate-sodium.</td></tr><tr><td><a href="/drugs/DB01399">Salsalate</a></td><td>The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, salsalate.</td></tr><tr><td><a href="/drugs/DB00418">Secobarbital</a></td><td>The barbiturate, secobarbital, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB00382">Tacrine</a></td><td>Tacrine and Fludrocortisone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects.</td></tr><tr><td><a href="/drugs/DB00306">Talbutal</a></td><td>The barbiturate, talbutal, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB00072">Trastuzumab</a></td><td>Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. </td></tr><tr><td><a href="/drugs/DB01401">Trisalicylate-choline</a></td><td>The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, trisalicylate-choline.</td></tr><tr><td><a href="/drugs/DB01339">Vecuronium</a></td><td>Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Fludrocortisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. </td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>The corticosteroid, fludrocortisone, alters the anticoagulant effect of warfarin.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid excess salt/sodium unless otherwise instructed by your physician.</li>
<li>Take with food to reduce irritation.</li></ul></td></tr></tbody></table>